We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
$1bn deal boosts D drug approach.
- Authors
O'Driscoll, Cath
- Abstract
The article reports on the possibility that Concert Pharmaceuticals Inc., a pharmaceutical company based in the U.S., would receive $1 billion in payments to co-develop and market the deuterated version of atazanavir, a protease inhibitor treatment for HIV developed by GlaxoSmithKline. It notes that the pharmaceutical company will receive an upfront payments of $35 million. Moreover, it pertains that the company's Phase I clinical trials on compound CTP-518 will start in 2009.
- Subjects
UNITED States; MEDICAL research; DRUG development; DRUG marketing; PHARMACEUTICAL industry; CONCERT Pharmaceuticals Inc.
- Publication
Chemistry & Industry, 2009, Issue 12, p7
- ISSN
0009-3068
- Publication type
Article